The Migraine Relief Center Blog

Here’s the latest from the Migraine Relief Center

Keep up with the doctors, patients, treatments—and results—from all our locations.

What Migraineurs Should Know About Coronavirus

By Migraine Relief Center on April 8, 2020

Migraineurs know how to self-isolate. With the threat of coronavirus literally in the air, the need for everyone to follow suit is essential. Also, you may be wondering if there is anything specific about the relationship between migraines and coronavirus.

Read More

Common Warning Signs of Imminent Migraine

By Migraine Relief Center on March 25, 2020

You might not have realized it, but your first migraine may have sent a warning ahead that it was coming. Many migraineurs have identified certain signs and symptoms that tend to show up a day or two ahead of an attack.

Read More

New Research Links Migraines and Visual Stimulation

By Migraine Relief Center on March 11, 2020

A new study published in NeuroImage Clinical found a potential link between migraines and activity in an individual’s visual cortex. Chun Yuen Fong, Wai Him Crystal Law, Jason Braithwaite, and Ali Mazaheri, researchers from the University of Birmingham and Lancaster University in the UK, collaborated in the paper published earlier this year.

Read More

A Review: Three Studies of the Effects of Cannabis on Migraines

By Migraine Relief Center on December 9, 2019

While the popularity of cannabidiol (CBD) continues to soar, there are still few studies available with data to support its use. Now that industrial hemp farming is legal, studies of hemp oil and CBD on migraines may become more available. Confounding some of the efforts is the fact that, while CBD is legal at the federal level, it is still illegal in some states. However, the trend appears to be toward the legalization of CBD in certain forms.

Read More

Digital Media and Migraines - The New Trigger?

By Migraine Relief Center on November 25, 2019

Up to 90% of migraineurs are sensitive to light, either before, during, or after a migraine attack.  That light sensitivity can be enough to trigger a migraine, and most digital media is light-based. So it makes sense that the use of digital devices and consuming digital media could trigger migraines in susceptible people. 

Read More

FDA Approval of Reyvow (rasmitidan) for Migraines

By Migraine Relief Center on November 11, 2019

People suffering from acute migraines will soon have another rescue medication at their disposal - The FDA approved Reyvow (lasmiditan hemisuccinate). The US Drug Enforcement Administration (DEA) has 90 days to review the drug to determine if it will be classified as a controlled substance. Once that three-month period is complete, the maker, Eli Lilly, and Company expect it to be available at retail pharmacies.

Read More

Ketamine and Migraines – A Wonder Drug?

By Migraine Relief Center on October 25, 2019

When a migraine doesn't respond to any other treatment, ketamine may offer relief. Operating differently than opioids, non-steroidal anti-inflammatories, and triptans, ketamine is increasingly available to treat chronic pain, migraine, and other health issues.

Read More

A Review of Electrical Nerve Stimulation

By Migraine Relief Center on October 11, 2019

Within the past decade, electrical nerve stimulation has been introduced as a potential non-drug treatment for individuals suffering migraines or cluster headaches. The approach varies slightly between techniques, and depending on the method, can be invasive or non-invasive.

Read More

Do You Have Episodic Migraines?

By Migraine Relief Center on September 30, 2019

Migraines come in several flavors, but one of the primary classifications is that of episodic migraine. Episodic migraines differ from chronic migraine disorder and may respond better to some treatments than chronic migraines.

Read More

What Are the Risks of Opioid Use for Migraineurs in This Age of Crisis?

By Migraine Relief Center on August 21, 2019

“Given the opioid epidemic in the U.S. and the high prevalence of opioid use in migraine patients shown in our study, especially those with chronic migraine, our results suggest that improved management of treatment is needed to optimize care.” - Justin S. Yu, PharmS, Allergan

Read More